The Effectiveness of Isoxsuprine in Patients With Intermittent Claudication

Skotnicki, S. H.; van Gaal, G.; Wijn, P. F. F.
November 1984
Angiology;Nov1984, Vol. 35 Issue 11, p685
Academic Journal
Sixty male patients with intermittent claudication were investigated in a randomized, double-blind, placebo-controlled study in order to determine the effectiveness of Isoxsuprine. The analysis of the results was made on the basis of subjective assessment of symptoms by the patients themselves and also on the results of segmental blood- pressure measurements and ankle/arm indices at rest and after standardised exercise. Significant differences were demonstrated between the active and placebo groups as regards pain-free walking distance although arterial pressure measurements did not show statistically significant differences between the two groups. Isoxsuprine appears to be significantly beneficial only for patients with ob- structions at the femoro-popliteal level.


Related Articles

  • Pentoxifylline in the Treatment of Intermittent Claudication of the Lower Limbs. Reich, Theobald; Cutler, Bruce C.; Lee, Bok Y.; Porter, John M.; Reichle, Frederick A.; Scogin, John T.; Strandness, D. Eugene // Angiology;Jul1984, Vol. 35 Issue 7, p389 

    Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily,...

  • Trental® 400 in the Treatment of Intermittent Claudication: Results of Long-Term, Placebo-Controlled Administration. Roekaerts, F.; Deleers, L. // Angiology;Jul1984, Vol. 35 Issue 7, p396 

    A double-blind, randomized, placebo-controlled long-term clinical study of Trental® 400 was carried out, partly under cross-over design, partly as a parallel-group study, in 36 patients suffering from chronic arterial obstructive disorders in the lower limbs, associated with intermittent...

  • Beneficial Effects of Intermittent Suction and Pressure Treatment in Intermittent Claudication. Mehlsen, Jesper; Himmelstrup, Holger; Himmelstrup, Bodil; Winther, Kaj; Trap-Jensen, Jens // Angiology;Jan1993 Supplement, Vol. 44, p16 

    The present study reports on the effects of a physical treatment modality in patients with intermittent claudication. During this treatment a major part of the skin surface is subjected to intermittent suction and pressure. In a previous, preliminary study the authors found a beneficial effect...

  • Optimal assessment of baseline treadmill walking performance in claudication clinical trials. Brass, Eric P.; Jiao, Jenny; Hiatt, William // Vascular Medicine;2007, Vol. 12 Issue 2, p97 

    Treadmill testing is frequently used to assess the functional capacity of patients with claudication, but the optimal application of treadmill testing in the setting of multicenter clinical trials remains uncertain. The current study used data from a recent clinical trial of the drug NM-702,...

  • Double-Blind Study of Papaverine Hydrochloride on the Efficacy in the Treatment of Intermittent Claudication. Seino, Yoshihiko; Rose, Harold B.; Kanazawa, Masakuni; Vyden, John K.; Wall, Francis J. // Angiology;Apr1983, Vol. 34 Issue 4, p257 

    A double-blind, placebo-controlled, parallel groups study design was utilized to evaluate the efficacy and the safety of papaverine HCL (PA, 300-1,500 mg/day) in the treatment of intermittent claudication. The study was in two phases: Phase 1-6 weeks duration with treadmill claudication tests...

  • Placebo-Controlled, Double-Blind Study of the Effect of Verapamil in Intermittent Claudication. Kimose, Hans-Henrik; Bagger, Jens Peder; Aagaard, Michael Trier; Paulsen, Peter Kildeberg // Angiology;Aug1990, Vol. 41 Issue 8, p595 

    The clinical effect of verapamil was tested in 24 patients with intermittent claudication in a randomized, placebo-controlled, double-blind, crossover study. Slow-release verapamil or placebo was given for two periods of three weeks. The walking distance, systemic blood pressure, and...

  • Silence of the Limbs: Pharmacological Symptomatic Treatment of Intermittent Claudication. De Backer, Tine; Vander Stichele, Robert; De Buyzere, Marc; De Backer, Guy; Van Bortel, Lucas // Current Vascular Pharmacology;May2010, Vol. 8 Issue 3, p383 

    Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules. Although spanning several decades, several studies underlying these claims were not...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • Functional Benefits of Peripheral Vascular Bypass Surgery for Patients with Intermittent Claudication. Regensteiner, Judith G.; Hargarten, Melanie E.; Rutherford, Robert B.; Hiatt, William R. // Angiology;Jan1993 Supplement, Vol. 44, p1 

    Many patients with peripheral arterial disease (PAD) undergo peripheral bypass surgery to relieve the symptom of intermittent claudication. However, measurement of graft patency alone, assessed by change in ankle blood pressure, may not adequately reflect the improvement in functional status...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics